Project Grant R41HL174447
Award Date
5/25/25
Completion Date
4/30/27
Dollars Obligated
$280K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $275,739 project grant under the Cardiovascular Diseases Research (CFDA 93.837) program to WR Biotech, LLC, a small disadvantaged business. The grant supports research on a novel technique called Improved Synchronization Modulation Electric Field (I-SMEF) to protect donor hearts and improve transplanted heart graft function during cold storage prior to heart transplantation in mice. The I-SMEF technique aims to maintain...
This $580,863 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of silicon nanowire-engineered human cardiac organoids for heart repair. The key products or services to be delivered include: Optimizing the surface roughness of electrically conductive silicon nanowires (e-SiNWs) to improve their electrical interactions with human pluripotent stem cell-derived cardiomyocytes...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $299,995 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Nanite Inc., a small disadvantaged business in Massachusetts. The grant will fund the development of computationally-designed polymer-based delivery vehicles for mRNA payloads to treat cystic fibrosis (CF), a debilitating genetic disorder affecting the lungs. The project aims to leverage computational modeling and high-throughput polymer...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $746,895.00 to the Regents of the University of Minnesota to establish a nonhuman primate heart model in gene-edited pigs. The objective is to leverage emerging gene editing technologies to engineer a macaque heart in a genetically modified porcine host, which would serve as an important platform for regenerative...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), has awarded a $700,398 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Trustees of Columbia University in the City of New York. This grant, awarded on July 1, 2024, with a final completion date of May 31, 2028, will support research to integrate spatial transcriptomics, genetics, and histomorphology to study causal mechanisms of atherosclerotic...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $827,665 to the New York Genome Center, Inc. (Nygc) to develop scalable methods for identifying causal genetic variants, relevant cell types, and target genes associated with cardiovascular disease (CVD). The key products and services to be delivered include: Performing colocalization of CVD and blood cell trait genome-wide association...
The federal Project Grant award R01HL175373, with a total funding amount of $402,911.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The primary objective of this grant is to develop a scalable method to generate a large number of therapeutic nanovesicles (NVs) from mesenchymal stem cells (MSCs) using an extrusion process. These engineered "cell-drones" will be investigated for...
This $817,208 Project Grant was awarded on January 3, 2025 by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research at the Broad Institute of MIT and Harvard to investigate the genetic basis and underlying mechanisms of heart failure (HF). The project will leverage high-throughput assays, including cell painting and Perturb-seq, to link genes associated with HF risk through genome-wide association...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a 4-year $1,458,982 Project Grant under the Cardiovascular Diseases Research Program (CFDA 93.837) to the Regents of the University of Michigan. The grant supports research to identify modulators of endoplasmic reticulum associated degradation (ERAD) activity that can enhance ex vivo expansion of hematopoietic stem cells (HSCs). The goal is to improve culture methods for the...
This National Heart, Lung, and Blood Institute (NHLBI) Project Grant award for $300,000, with a performance period from September 10, 2024 to September 9, 2025, supports research by Gigamune, Inc. to develop an in vivo gene therapy for sickle cell disease using a novel lentiviral vector technology. The project aims to assess the efficiency and specificity of the company's "GigaLenti" lentiviral vector platform in delivering CRISPR/Cas9 gene editing machinery to knockout the BCL11A...